Flash Forward is a show about possible (and not so possible) future scenarios. What would the warranty on a sex robot look like? How would diplomacy work if we couldn’t lie? Could there ever be a fecal transplant black market? (Complicated, it wouldn’t, and yes, respectively, in case you’re curious.) Hosted and produced by award winning science journalist Rose Eveleth, each episode combines audio drama and journalism to go deep on potential tomorrows, and uncovers what those futures might re ...
…
continue reading
Kandungan disediakan oleh Oleksandr Yagensky. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh Oleksandr Yagensky atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.
Player FM - Aplikasi Podcast
Pergi ke luar talian dengan aplikasi Player FM !
Pergi ke luar talian dengan aplikasi Player FM !
Ep#040: Eliminating Cancer Using Invariant Natural Killer T Cells (iNKTs) with Dr. Jennifer Buell
MP3•Laman utama episod
Manage episode 324873457 series 2800366
Kandungan disediakan oleh Oleksandr Yagensky. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh Oleksandr Yagensky atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.
Welcome to the next episode of the Personalized Medicine Podcast. On this podcast we have talked extensively about antibody, vaccine and CAR-T cell based approaches to treat cancer. Today we will be talking about a new approach in oncology that is based on invariant Natural Killer T Cells, or iNKTs.
Our guest today is Dr. Jennifer Buell, the founder, CEO and President of MiNK Therapeutics and the former President and COO of Agenus. Jennifer has over 25 years of experience in the biopharmaceutical space, having held multiple leadership positions at biotech companies. In her tenure at Agenus, she transformed a neoantigen vaccine development startup into a multifaceted company with a strong global footing. She is now leading MiNK therapeutics, the precision oncology company that develops targeted iNKT cells for treatment of various types of cancer and autoimmune diseases.
Together with Jennifer we discussed:
◦ Evolution of immunooncology over the the last two decades
◦ Role of immune system in fighting cancer
◦ Neoantigen vaccines as a tool for personalized cancer treatment
◦ Invariant Natural Killer T Cells (iNKTs) and their role in combating cancer
◦ Advantage of iNKTs over other cancer treatments
◦ Potential of combination therapies in oncology
◦ Challenges in bringing novel cell-based therapies to the market
◦ Advice to budding biotech entrepreneurs
◦ The outlook on the next decade of cancer treatment
Get in touch with Jennifer:
LinkedIn: Jennifer S. Buell
Twitter: @jbuell01
Web: https://minktherapeutics.com/
…
continue reading
Our guest today is Dr. Jennifer Buell, the founder, CEO and President of MiNK Therapeutics and the former President and COO of Agenus. Jennifer has over 25 years of experience in the biopharmaceutical space, having held multiple leadership positions at biotech companies. In her tenure at Agenus, she transformed a neoantigen vaccine development startup into a multifaceted company with a strong global footing. She is now leading MiNK therapeutics, the precision oncology company that develops targeted iNKT cells for treatment of various types of cancer and autoimmune diseases.
Together with Jennifer we discussed:
◦ Evolution of immunooncology over the the last two decades
◦ Role of immune system in fighting cancer
◦ Neoantigen vaccines as a tool for personalized cancer treatment
◦ Invariant Natural Killer T Cells (iNKTs) and their role in combating cancer
◦ Advantage of iNKTs over other cancer treatments
◦ Potential of combination therapies in oncology
◦ Challenges in bringing novel cell-based therapies to the market
◦ Advice to budding biotech entrepreneurs
◦ The outlook on the next decade of cancer treatment
Get in touch with Jennifer:
LinkedIn: Jennifer S. Buell
Twitter: @jbuell01
Web: https://minktherapeutics.com/
48 episod
MP3•Laman utama episod
Manage episode 324873457 series 2800366
Kandungan disediakan oleh Oleksandr Yagensky. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh Oleksandr Yagensky atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.
Welcome to the next episode of the Personalized Medicine Podcast. On this podcast we have talked extensively about antibody, vaccine and CAR-T cell based approaches to treat cancer. Today we will be talking about a new approach in oncology that is based on invariant Natural Killer T Cells, or iNKTs.
Our guest today is Dr. Jennifer Buell, the founder, CEO and President of MiNK Therapeutics and the former President and COO of Agenus. Jennifer has over 25 years of experience in the biopharmaceutical space, having held multiple leadership positions at biotech companies. In her tenure at Agenus, she transformed a neoantigen vaccine development startup into a multifaceted company with a strong global footing. She is now leading MiNK therapeutics, the precision oncology company that develops targeted iNKT cells for treatment of various types of cancer and autoimmune diseases.
Together with Jennifer we discussed:
◦ Evolution of immunooncology over the the last two decades
◦ Role of immune system in fighting cancer
◦ Neoantigen vaccines as a tool for personalized cancer treatment
◦ Invariant Natural Killer T Cells (iNKTs) and their role in combating cancer
◦ Advantage of iNKTs over other cancer treatments
◦ Potential of combination therapies in oncology
◦ Challenges in bringing novel cell-based therapies to the market
◦ Advice to budding biotech entrepreneurs
◦ The outlook on the next decade of cancer treatment
Get in touch with Jennifer:
LinkedIn: Jennifer S. Buell
Twitter: @jbuell01
Web: https://minktherapeutics.com/
…
continue reading
Our guest today is Dr. Jennifer Buell, the founder, CEO and President of MiNK Therapeutics and the former President and COO of Agenus. Jennifer has over 25 years of experience in the biopharmaceutical space, having held multiple leadership positions at biotech companies. In her tenure at Agenus, she transformed a neoantigen vaccine development startup into a multifaceted company with a strong global footing. She is now leading MiNK therapeutics, the precision oncology company that develops targeted iNKT cells for treatment of various types of cancer and autoimmune diseases.
Together with Jennifer we discussed:
◦ Evolution of immunooncology over the the last two decades
◦ Role of immune system in fighting cancer
◦ Neoantigen vaccines as a tool for personalized cancer treatment
◦ Invariant Natural Killer T Cells (iNKTs) and their role in combating cancer
◦ Advantage of iNKTs over other cancer treatments
◦ Potential of combination therapies in oncology
◦ Challenges in bringing novel cell-based therapies to the market
◦ Advice to budding biotech entrepreneurs
◦ The outlook on the next decade of cancer treatment
Get in touch with Jennifer:
LinkedIn: Jennifer S. Buell
Twitter: @jbuell01
Web: https://minktherapeutics.com/
48 episod
Semua episod
×Selamat datang ke Player FM
Player FM mengimbas laman-laman web bagi podcast berkualiti tinggi untuk anda nikmati sekarang. Ia merupakan aplikasi podcast terbaik dan berfungsi untuk Android, iPhone, dan web. Daftar untuk melaraskan langganan merentasi peranti.